For more than 35 years, Gilead has been a pioneer in virology and has helped transform the treatment and prevention landscape in HIV.  Thanks in large part to the company’s work, HIV has evolved from what was once considered a death sentence into a manageable and preventable condition. Now Gilead has its sights set on helping end the epidemic.

“Going after an HIV cure presents one of the greatest scientific challenges of our time,” says Devi Sengupta, Executive Director and HIV Cure Global Lead at Gilead. “It may be a moonshot, but we're not running blindly towards it.”

Gilead knows that scientific innovation alone can’t end the epidemic. Stigma, inequities and barriers to care continue to prevent medications from reaching individuals who need it. That’s why the company partners alongside community and organizations around the world to meet people where they are and help close these gaps in care.

Watch the video above to learn more about Gilead’s legacy in virology and its ongoing commitment to end the HIV epidemic.